Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Clinical trial NCT02323113 · TERMINATED
Trial details
- NCT number
- NCT02323113
- Sponsor
- Calithera Biosciences, Inc
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-09
- Primary completion
- 2018-06-08
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.